BioCryst_PrimaryLogo_R_2C_RGB.jpg
BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets
22 nov. 2021 07h00 HE | BioCryst Pharmaceuticals, Inc.
—Provides funding for BCX9930/oral Factor D program across multiple indications— —Agreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity— NEW YORK,...
BioCryst.jpg
BioCryst Reports First Quarter 2020 Financial Results and Upcoming Key Milestones
06 mai 2020 07h00 HE | BioCryst Pharmaceuticals, Inc.
—Berotralstat approval/launch timelines in U.S., Japan, EU remain on track— —Early clinical data supports BCX9930 as oral monotherapy for complement-mediated diseases— —Patient dosing underway in...
BioCryst.jpg
BioCryst Reports Data From Phase 1 Trial of BCX9930 and Announces Plans to Advance Program Into Proof of Concept Study in PNH Patients
28 oct. 2019 06h59 HE | BioCryst Pharmaceuticals, Inc.
—Phase 1 data showed rapid, sustained and >95% inhibition of alternative pathway of complement system with 100 mg of oral BCX9930 BID— —BCX9930 safe and generally well tolerated— —Part 1 SAD and...
BioCryst.jpg
Biocryst Begins Enrollment of Phase 1 Trial of BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases
27 juin 2019 16h15 HE | BioCryst Pharmaceuticals, Inc.
—Data expected in Q4 2019— —BCX9930 showed high potency, specificity, suppression of hemolysis and wide safety margin in preclinical studies— RESEARCH TRIANGLE PARK, N.C., June 27, 2019 (GLOBE...
BioCryst.jpg
BioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors
20 nov. 2018 07h00 HE | BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed Theresa Heggie to its Board of Directors. ...
BioCryst.jpg
BioCryst Reports Third Quarter 2018 Financial Results
06 nov. 2018 07h00 HE | BioCryst Pharmaceuticals, Inc.
APeX-2 study enrollment completed, results on-track for Q2 2019 RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced...
BioCryst.jpg
BioCryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
05 nov. 2018 07h00 HE | BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present three abstracts at the upcoming Annual...